Reviva Pharmaceuticals Holdings Inc (RVPH)
1.35
+0.01
(+0.75%)
USD |
NASDAQ |
Sep 27, 16:00
1.34
-0.01
(-0.74%)
After-Hours: 20:00
Reviva Pharmaceuticals Holdings SG&A Expense (TTM): 8.188M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 8.188M |
| March 31, 2024 | 8.722M |
| December 31, 2023 | 8.084M |
| September 30, 2023 | 8.048M |
| June 30, 2023 | 7.313M |
| March 31, 2023 | 5.239M |
| Date | Value |
|---|---|
| December 31, 2022 | 5.359M |
| September 30, 2022 | 5.184M |
| June 30, 2022 | 4.981M |
| March 31, 2022 | 5.391M |
| December 31, 2021 | 5.252M |
| September 30, 2021 | 4.477M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
4.477M
Minimum
Sep 2021
8.722M
Maximum
Mar 2024
6.353M
Average
5.375M
Median
SG&A Expense (TTM) Benchmarks
| Eyenovia Inc | 13.74M |
| NovaBay Pharmaceuticals Inc | 11.53M |
| Palatin Technologies Inc | 13.34M |
| iBio Inc | 11.67M |
| Theriva Biologics Inc | 5.633M |